E-cadherin mRNA expression analysis in evaluating the natural history of urothelial bladder cell carcinoma: Results from a long-term follow-up study

Oncology Reports

Volumn 17, Issue 4, 2007, Pages 925-930

  Cai, Tommaso ^a   Piazzini, Mauro ^a   Nesi, Gabriella ^a   Taddei, Ilaria ^a   Sardi, Iacopo ^a   Detti, Beatrice ^a   Mondaini, Nicola ^a   Dal Canto, Maurizio ^a   Bartoletti, Riccardo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Bladder cancer; E cadherin; mRNA; Northern blot analysis; Progression; Recurrence; Urothelial cell carcinoma

Indexed keywords

CADHERIN; MESSENGER RNA;

AGED; ARTICLE; BLADDER TUMOR; CARCINOMA; DISEASE COURSE; FEMALE; FOLLOW UP; GENETICS; HUMAN; MALE; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE; UROTHELIUM;

AGED; CADHERINS; CARCINOMA; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RNA, MESSENGER; SURVIVAL RATE; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 34249937476     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.17.4.925     Document Type: Article

References (31)

1. Tsukino H, Kuroda Y, Nakao H, et al: E-cadherin gene polymorphism and risk of urothelial cancer. Cancer Lett 195: 53-58, 2003. (Pubitemid 36588978)
2. Garcea G, Neal CP, Pattenden CJ, Steward WP and Berry DP: Molecular prognostic marker in pancreatic cancer: a systematic review. Eur J Cancer 41: 2213-2236, 2005. (Pubitemid 41415597)
3. Mareel M, Boterberg T, Noe V, et al: E-cadherin/catenin/cytoskeleton complex: a regulator of cancer invasion. J Cell Physiol 173: 271-274, 1997. (Pubitemid 27481143)
4. Okegawa T, Li Y, Pong RC and Hsieh JT: Cell adhesion proteins as tumor suppressors. J Urol 167: 1836-1843, 2002. (Pubitemid 34240766)
5. Bryan RT, Hussain SA, James ND, Jankowski JA and Wallace DMA: Molecular pathways in bladder cancer: Part 2. BJU Int 95: 491-496, 2005. (Pubitemid 40311457)
6. Frixen UH, Behrens J, Sachs M, Eberle G, et al : E-cadherinmediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 113: 173-185, 1991. (Pubitemid 21909684)
7. Oka H, Shiozaki H, Kobayashi K, et al: Expression of E-cadherin cell adhesion molecules in human breast cancer tissue and its relationship to metastasis. Cancer Res 53: 1696-1701, 1993. (Pubitemid 23113254)
8. Nigam AK, Savage FJ, Boulos PB, Stamp GWH, Liu D and Pignatelli M: Loss of cell-cell and cell-matrix adhesion molecules in colorectal cancer. Br J Cancer 68: 507-514, 1993. (Pubitemid 23258453)
9. Bendardaf R, Elzagheid A, Lamlum H, Ristamaki R, Collan Y and Pyrhonen S: E-cadherin, CD44s and CD44v6 correlate with tumour differentiation in colorectal cancer. Oncol Rep 13: 831-835, 2005.
10. Umbas R, Isaacs WB, Bringuier PP, et al: Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 54: 3929-3933, 1994. (Pubitemid 24241218)
11. Fromont G, Rouprêt M, Amira N, et al: Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma. Eur Urol 48: 764-770, 2005. (Pubitemid 41495375)
12. Byrne RR, Shariat SF, Brown R, et al: E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term follow-up. J Urol 165: 1473-1479, 2001. (Pubitemid 32410217)
13. Hong R, Pu Y, Hsieh T, Chu JS and Lee WJ: Expressions of E-cadherin and exon V6-containing isoforms of CD44 and their prognostic values in human transitional cell carcinoma. J Urol 153: 2025-2028, 1995.
14. Heney NM, Ahmed S, Flanagan MJ, et al: Superficial bladder cancer: progression and recurrence. J Urol 130: 1083-1086, 1983. (Pubitemid 14207227)
15. Cai T, Margallo E, Nesi G, Giubilei G, Rizzo M and Bartoletti R: Prognostic value of static cytometry in transitional cell carcinoma of the bladder: recurrence rate and survival in a group of patients at 10 years follow-up. Oncol Rep 15: 213-219, 2006.
16. Taddei I, Piazzini M, Bartoletti R, Dal Canto M and Sardi I: Molecular alterations of E-cadherin gene: possible role in human bladder carcinogenesis. Int J Mol Med 6: 201-208, 2000.
17. Oosterlinck W, Lobel B, Jakse G, Malmström P, Stöckle M and Sternberg C (The EAU Working Group on Oncological Urology): Guidelines on Bladder Cancer. Eur Urol 41: 105-112, 2002.
18. UICC International Union Against Cancer: TNM classification of malignant tumors. 6th edition. Wiley-Liss, New York, pp199-202, 2002.
19. Mostofi FK, Sobin LH and Torloni H: Histological typing of urinary bladder tumours. World Health Organization, Geneva, 1973.
20. Bartoletti R, Cai T, Nesi G, Sardi I and Rizzo M: Qualitative and quantitative analysis of angiogenetic factors in transitional cell bladder carcinoma: relationship with clinical course at 10 years follow-up. Oncol Rep 14: 251-255, 2005.
21. Chomczynski P and Sacchi N: Single step method of RNA isolation by acid guanidinium thiocyanate-phenol cloroform extraction. Anal Biochem 162: 156-159, 1987. (Pubitemid 17064313)
22. Sambrook J: Molecular cloning: a laboratory manual. 2nd edition. Cold Spring Harbor Laboratories Press, Cold Spring Harbor, NY, 1989.
23. Pertschuk LP, Feldman JG, Kim DS, et al: Steroid hormone receptor immunohistochemistry and amplification of c-myc protooncogene. Relationship to disease-free survival in breast cancer. Cancer 71: 162-171, 1993. (Pubitemid 23019297)
24. Serdar A, Turhan C, Soner G, et al: The prognostic importance of e-cadherin and p53 gene expression in transitional bladder carcinoma patients. Int Urol Nephrol 37: 485-492, 2005. (Pubitemid 41762502)
25. Takeichi M: Cadherin cell adhesion receptors as a morphogenetic regulator. Science 251: 1451-1455, 1991.
26. Garcia del Muro X, Torregrosa A, Munoz J, et al: Prognostic value of the expression of E-cadherin and beta-catenin in bladder cancer. Eur J Cancer 36: 357-362, 2000. (Pubitemid 30116732)
27. Syrigos KN, Krausz T, Waxman J, et al: E-cadherin expression in bladder cancer using formalin-fixed, paraffin-embedded tissues: correlation with histopathological grade, tumor stage and survival. Int J Cancer 64: 367-370, 1995. (Pubitemid 26051671)
28. Lipponen PK and Eskelinen MJ: Reduced expression of Ecadherin is related to invasive disease and frequent recurrence in bladder cancer. J Cancer Res Clin Oncol 121: 303-308, 1985.
29. Bringuier PP, Umbas R, Schaafsma E, Karthaus HF, Debruyne FM and Schalken JA: Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res 53: 3241-3245, 1993. (Pubitemid 23223289)
30. Mialhe A, Louis J, Montlevier S, et al: Expression of E-cadherin, alfa-, beta- and gamma-catenins in human bladder carcinomas: are they good prognostic factors? Invasion Metastasis 17: 124-137, 1997. (Pubitemid 28379686)
31. Mahnken A, Kausch I, Feller AC and Kruger S: E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder. Oncol Rep 14: 1065-1070, 2005.